发明申请
US20100210552A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
审中-公开
人类GLUCAGON-LIKE PEPTIDE-1 MIMICS及其在治疗糖尿病及相关病症中的应用
- 专利标题： HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
- 专利标题（中）： 人类GLUCAGON-LIKE PEPTIDE-1 MIMICS及其在治疗糖尿病及相关病症中的应用
-
申请号： US12771096申请日： 2010-04-30
-
公开(公告)号： US20100210552A1公开(公告)日： 2010-08-19
- 发明人: Sesha Iyer Natarajan , Claudio Mapelli , Margarita M. Bastos , Michael Bernatowicz , Ving Lee , William R. Ewing
- 申请人： Sesha Iyer Natarajan , Claudio Mapelli , Margarita M. Bastos , Michael Bernatowicz , Ving Lee , William R. Ewing
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 主分类号： A61K38/16
- IPC分类号： A61K38/16 ; C07K14/00 ; C07K7/00 ; A61K38/04 ; A61P3/04 ; A61P3/06 ; A61P3/10 ; A61P9/12
摘要：
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.
信息查询
IPC分类:
